Back to News
Market Impact: 0.4
What Precigen (PGEN) Said on Its Q3 Earnings Call
Source: marketbeat.com
Corporate EarningsCompany FundamentalsHealthcare & Biotech
Precigen reported $72.9 million in third-quarter 2026 PAPZIMEOS sales for adults with recurrent respiratory papillomatosis. The company posted its second consecutive profitable quarter and generated positive cash flow earlier than previously expected.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
PGEN0.80
More News
- Citizens raises Precigen stock price target to $12 on strong sales
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request